A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 164,834 shares of LLY stock, worth $131 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
164,834
Previous 167,879 1.81%
Holding current value
$131 Million
Previous $152 Million 3.92%
% of portfolio
0.5%
Previous 0.56%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$772.14 - $960.02 $2.35 Million - $2.92 Million
-3,045 Reduced 1.81%
164,834 $146 Million
Q2 2024

Jul 26, 2024

BUY
$724.87 - $909.04 $1.77 Million - $2.22 Million
2,446 Added 1.48%
167,879 $152 Million
Q1 2024

Apr 24, 2024

BUY
$592.2 - $792.28 $2.11 Million - $2.82 Million
3,559 Added 2.2%
165,433 $129 Million
Q4 2023

Feb 09, 2024

SELL
$525.19 - $619.13 $1.99 Million - $2.34 Million
-3,784 Reduced 2.28%
161,874 $94.4 Million
Q3 2023

Oct 24, 2023

SELL
$434.7 - $599.3 $3.35 Million - $4.62 Million
-7,717 Reduced 4.45%
165,658 $89 Million
Q2 2023

Jul 13, 2023

BUY
$350.74 - $468.98 $7.21 Million - $9.64 Million
20,551 Added 13.45%
173,375 $81.3 Million
Q1 2023

May 11, 2023

BUY
$310.63 - $364.82 $2.53 Million - $2.97 Million
8,149 Added 5.63%
152,824 $52.5 Million
Q4 2022

Feb 08, 2023

BUY
$321.55 - $374.67 $2.24 Million - $2.61 Million
6,975 Added 5.07%
144,675 $52.9 Million
Q3 2022

Oct 17, 2022

BUY
$296.48 - $337.87 $3.51 Million - $4 Million
11,846 Added 9.41%
137,700 $44.5 Million
Q2 2022

Jul 13, 2022

SELL
$278.73 - $327.27 $324,720 - $381,269
-1,165 Reduced 0.92%
125,854 $40.8 Million
Q1 2022

May 12, 2022

BUY
$234.69 - $291.66 $4.71 Million - $5.86 Million
20,089 Added 18.79%
127,019 $36.4 Million
Q4 2021

Feb 03, 2022

BUY
$224.85 - $279.04 $1.16 Million - $1.44 Million
5,164 Added 5.07%
106,930 $29.5 Million
Q3 2021

Nov 02, 2021

SELL
$221.6 - $272.71 $394,891 - $485,969
-1,782 Reduced 1.72%
101,766 $23.5 Million
Q2 2021

Aug 10, 2021

SELL
$180.55 - $233.54 $685,728 - $886,984
-3,798 Reduced 3.54%
103,548 $23.8 Million
Q1 2021

May 07, 2021

BUY
$164.32 - $212.72 $664,838 - $860,665
4,046 Added 3.92%
107,346 $20.1 Million
Q4 2020

Feb 04, 2021

SELL
$130.46 - $172.63 $320,409 - $423,979
-2,456 Reduced 2.32%
103,300 $17.4 Million
Q3 2020

Oct 29, 2020

BUY
$146.22 - $169.13 $777,013 - $898,756
5,314 Added 5.29%
105,756 $15.7 Million
Q2 2020

Jul 27, 2020

BUY
$136.42 - $164.18 $430,132 - $517,659
3,153 Added 3.24%
100,442 $16.5 Million
Q1 2020

May 08, 2020

SELL
$119.05 - $147.35 $672,394 - $832,232
-5,648 Reduced 5.49%
97,289 $13.5 Million
Q4 2019

Feb 04, 2020

BUY
$106.92 - $132.43 $292,640 - $362,460
2,737 Added 2.73%
102,937 $13.5 Million
Q3 2019

Nov 06, 2019

SELL
$106.79 - $116.16 $141,176 - $153,563
-1,322 Reduced 1.3%
100,200 $11.2 Million
Q3 2019

Oct 28, 2019

SELL
$106.79 - $116.16 $81,160 - $88,281
-760 Reduced 0.74%
101,522 $11.4 Million
Q2 2019

Aug 15, 2019

SELL
$110.79 - $129.32 $100,929 - $117,810
-911 Reduced 0.88%
102,282 $0
Q1 2019

May 08, 2019

SELL
$111.31 - $131.02 $5.5 Million - $6.48 Million
-49,451 Reduced 32.4%
103,193 $0
Q4 2018

Feb 05, 2019

SELL
$105.9 - $118.64 $269,939 - $302,413
-2,549 Reduced 1.64%
152,644 $17.7 Million
Q3 2018

Nov 02, 2018

BUY
$85.86 - $107.31 $505,629 - $631,948
5,889 Added 3.94%
155,193 $0
Q2 2018

Aug 10, 2018

SELL
$75.7 - $86.88 $351,853 - $403,818
-4,648 Reduced 3.02%
149,304 $0
Q1 2018

May 09, 2018

BUY
$74.21 - $87.6 $3.56 Million - $4.2 Million
47,938 Added 45.22%
153,952 $0
Q4 2017

Feb 22, 2018

BUY
$81.94 - $87.89 $559,650 - $600,288
6,830 Added 6.89%
106,014 $0
Q3 2017

Nov 07, 2017

BUY
$77.07 - $85.54 $1.04 Million - $1.16 Million
13,542 Added 15.81%
99,184 $8.48 Million
Q2 2017

Aug 08, 2017

BUY
N/A
85,642
85,642 $7.05 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.